Weight-loss drugs are typically not covered by private insurance plans, and in late November, President Joe Biden proposed expanding coverage for these medications for Americans insured by Medicare ...

Per Lilly, this is its single-largest manufacturing investment in the country outside its home state. It plans to start ...

Ozempic and other GLP-1 drugs have surged in popularity, dominating U.S. medication spending in 2023 for their effectiveness in managing diabetes and promoting weight loss. As demand grows, promising ...

Rybelsus (semaglutide ... Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining ...

LLY's obesity drug, Zepbound, shows an average weight loss of 20.2%, superior to 13.7% for NVO's Wegovy in a head-to-head ...

The latest Health Survey for England shows that 64% of adults were overweight or obese in 2022. However, Dr Kath McCullough, ...

The demand for GLP-1 drugs (like Wegovy and several others) continues to grow. Despite this escalating demand, the prices for ...

Research shows an average weight loss of just 5% could save an annual $153bn in medical fees and lost productivity.

The NHS spending watchdog said about 220,000 people could benefit from the drug in an initial three-year period ...

Mounjaro will be made available on the NHS but the rollout will be phased - only those with the highest need will get the ...

Joe Breen, 38, is one of thousands of people whose experiences with GLP-1s such as Ozempic and Wegovy have radically changed their relationship with alcohol. Are these drugs the future for treating ...

MILLIONS of Brits “will have to wait” to take a lifesaving fat loss jab dubbed the “King Kong of weight loss drugs”. Fewer ...